Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Acronyms IBU-ALS-1201
  • Sponsors MediciNova
  • Most Recent Events

    • 04 Dec 2019 According to a MediciNova media release, results of additional analyses from the study will be presented at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) 2019.
    • 04 Dec 2019 Results from additional analyses presented in a MediciNova media release.
    • 29 Jul 2019 According to a MediciNova media release, data from the study will be presented at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease).
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top